Regnum Corp. (RGMP) Research

Regnum Corp. is dedicated to advancing and marketing therapeutic agents designed to combat both rare and infectious diseases. Its flagship product is Leronlimab (PRO 140), a monoclonal antibody functioning as a C-C chemokine receptor type 5 (CCR5) antagonist. This drug is specifically formulated to inhibit the human immunodeficiency virus (HIV) from gaining entry into human cells. Headquartered in New York, New York, Regnum Corp. operates as a subsidiary of Phoenixus AG.

Market snapshot

Symbol
RGMP
Price
$0.00
Day change
0.00%
Market cap
$2.3K
P/E ratio
-0.00x
52-week range
0.0001-0.0001
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Ampio Pharmaceuticals, Inc. (AMPE)
  • Bioasis Technologies Inc. (BIOAF)
  • Golden Developing Solutions, Inc. (DVLP)
  • Lombard Medical, Inc. (EVARF)
  • GB Sciences, Inc. (GBLX)
  • GlobeStar Therapeutics Corporation (GSTC)
  • IR Biosciences Holdings Inc. (IRBS)
  • Neptune Wellness Solutions Inc. (NEPTF)

Open Regnum Corp. (RGMP) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.